Description du projet
Une solution technologique innovante pour un dosage intelligent dans les cas de TDAH
Le trouble déficitaire de l’attention avec hyperactivité (TDAH) est un trouble neurocomportemental qui se manifeste très tôt et associe le manque d’attention à l’hyperactivité, ce qui nuit à de nombreux aspects de la vie des enfants concernés. Les stimulants constituent la principale classe de médicaments efficace contre le TDAH, mais ils sont classés comme des substances contrôlées, et associés à des effets secondaires et à de potentiels abus. Ils nécessitent un ajustement de la dose prescrite tout au long de la vie du patient. L’objectif du projet OnDosis01, financé par l’UE, est de mettre au point un dispositif thérapeutique qui permette une gestion efficace du TDAH. Cette technologie introduira une nouvelle façon d’administrer le traitement, en intégrant auto-surveillance de la médication et dosage intelligent. Cette intégration simplifiera l’ajustement de la dose, ce qui permettra d’améliorer l’observance du traitement et de réduire le risque grâce une protection accrue contre de potentiels abus.
Objectif
The goal of this project is to develop a therapy that allows for more effective management of attention-deficit hyperactivity disorder (ADHD). ADHD is a common, childhood onset, neurobehavioural disorder characterised by a combination of inattention, hyperactivity and impulsivity impairing multiple areas of life. Stimulants are the most widely used ADHD medications and are proven effective on ADHD symptoms, but classified as controlled substances they are associated with concerns about side effects and potential for abuse. In addition, they require careful dose titration at initiation and throughout the patients’ life.
OnDosis aims to address these challenges by developing a novel “combination product”, prescribed as an ADHD treatment regime, that combines a technological platform with stimulant active compounds. This integrated solution will simplify dose titration, enable ease of swallowing, offer adherence support and self-monitoring checks. Importantly, OnDosis’ solution is a personalised device with the potential to reduce risk for medication abuse through tamper resistance and tamper evident features.
The ultimate success of the project will depend on generation of clinical data which will support partnering and out-licensing. OnDosis plans to apply for SMEi Phase 2 grant to take the product through required clinical studies, and then go to market through a licensing agreement with a strong commercial partner. OnDosis has a strong network established with potential pharma partners and investors, and has already gained support from investors that offer strategic support to the company.
The burden of ADHD is increasing and the unmet need is growing. This encourages OnDosis in the endeavour of a needs-driven research to address this widespread challenge. Market research with several stakeholders in healthcare have convinced OnDosis of the potential to bring significant impact to patients with ADHD through this novel technology.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
431 50 MOLNDAL
Suède
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.